Cargando…

Sex Hormones and Calcitonin Gene–Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study

BACKGROUND AND OBJECTIVES: Sex hormones may modulate calcitonin gene-related peptide (CGRP) release in the trigeminovascular system. We studied CGRP concentrations in plasma and tear fluid in female participants with episodic migraine (EM) and a regular menstrual cycle (RMC), female participants wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raffaelli, Bianca, Storch, Elisabeth, Overeem, Lucas Hendrik, Terhart, Maria, Fitzek, Mira Pauline, Lange, Kristin Sophie, Reuter, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136010/ https://www.ncbi.nlm.nih.gov/pubmed/36813730 http://dx.doi.org/10.1212/WNL.0000000000207114

Ejemplares similares

Migraine and Hormonal Contraception in Gynecological Outpatient Care—Cross-Sectional Study among Practicing Gynecologists in Germany
por: Fitzek, Mira P., et al.
Publicado: (2023)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Patients’ and Health Care Workers’ Perception of Migraine Images on the Internet: Cross-sectional Survey Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
por: Hong, Ja Bin, et al.
Publicado: (2023)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2022)

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Perception of typical migraine images on the internet: Comparison between a metropolis and a smaller rural city in Germany
por: Hamann, Till, et al.
Publicado: (2023)

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2020)

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
por: Hong, Ja Bin, et al.
Publicado: (2023)

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Serum tau protein elevation in migraine: a cross-sectional case–control study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Male and female sex hormones in primary headaches
por: Delaruelle, Zoë, et al.
Publicado: (2018)

The sense of stopping migraine prophylaxis
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Determining the Evolution of Headache Among Regular Users of a Daily Electronic Diary via a Smartphone App: Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

Editorial: Spotlight on resistant and refractory migraine
por: Ornello, Raffaele, et al.
Publicado: (2023)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Calcitonin, the forgotten hormone: does it deserve to be forgotten?
por: Felsenfeld, Arnold J., et al.
Publicado: (2015)

Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine
por: Fila, Michal, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Effects of intracerebroventricular administration of calcitonin gene-related peptide (CGRP) on sex hormones and sperm quality in rats
por: Rahimi, Kaveh, et al.
Publicado: (2023)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Environmental Factors That Affect Parathyroid Hormone and Calcitonin Levels
por: Babić Leko, Mirjana, et al.
Publicado: (2021)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)

Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients
por: Lassen, L. H., et al.
Publicado: (2008)

The influence of weather on migraine – are migraine attacks predictable?
por: Hoffmann, Jan, et al.
Publicado: (2015)

Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks
por: Han, Dawei
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3ev59rssl9idofogif1qf76v8t